Yonehiro Grant 4

What Happened

• Yonehiro Grant, Chief Operating Officer of Bolt Biotherapeutics (BOLT), received a grant of 10,000 derivative shares (reported as an option award) on January 28, 2026. The filing reports a $0.00 price for the award (no cash paid at grant) and a total reported value of $0.

Key Details

• Transaction date: 2026-01-28; filing date (Form 4): 2026-02-04.
• Amount: 10,000 shares reported as a derivative award (option); reported price $0.00; reported total value $0.
• Vesting: Per the filing footnote, the option vests 1/36th of the shares upon completion of each month of continuous service following January 1, 2026 (36-month monthly vesting).
• Shares owned after transaction: not specified in the details provided.
• Timeliness: The Form 4 was filed on Feb 4, 2026 for a Jan 28, 2026 transaction, which is later than the SEC’s typical two-business-day reporting window.

Context

• This is a compensation-related option grant that vests over time based on continued service; it is not an immediate open-market purchase or sale. Such awards are common for executives and are intended to retain and incentivize future service rather than signal immediate trading intent.